Sophia Genetics SA (SOPH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $703.25M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sophia Genetics SA (SOPH) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Sophia Genetics SA reported EPS of -$0.24, below the -$0.13 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SOPH's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
SOPH Earnings Call
The latest SOPH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, SOPH beat 14, missed 6 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.27M, up 24.7% from $19.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.24 | -$0.13 | N/A | -84.62% | Miss | N/A | 1 | 0 up, 1 down | Nov 3, 2026 | $24.27M |
| Jun 30, 2026 | -$0.26 | -$0.15 | N/A | -73.33% | Miss | N/A | 1 | 1 up, 0 down | Aug 4, 2026 | $23.31M |
| Mar 31, 2026 | -$0.19 | -$0.24 | -$0.24 - -$0.24 | +20.83% | Beat | N/A | 1 | 1 up, 0 down | May 5, 2026 | $21.69M |
| Dec 31, 2025 | -$0.17 | -$0.22 | N/A | +22.41% | Beat | N/A | 1 | 0 up, 1 down | Mar 3, 2026 | $21.71M |
| Sep 30, 2025 | -$0.20 | -$0.20 | -$0.20 - -$0.20 | 0.00% | In line | N/A | 1 | 0 up, 2 down | Nov 4, 2025 | $19.46M |
| Jun 30, 2025 | -$0.25 | -$0.17 | -$0.19 - -$0.15 | -47.06% | Miss | N/A | 2 | 1 up, 1 down | Aug 5, 2025 | $18.32M |
| Mar 31, 2025 | -$0.18 | -$0.19 | -$0.24 - -$0.15 | +5.26% | Beat | N/A | 2 | 1 up, 1 down | May 6, 2025 | $17.78M |
| Dec 31, 2024 | -$0.12 | -$0.15 | -$0.16 - -$0.14 | +20.07% | Beat | N/A | 2 | 0 up, 1 down | Mar 4, 2025 | $17.73M |
| Sep 30, 2024 | -$0.21 | -$0.18 | -$0.27 - -$0.17 | -16.67% | Miss | N/A | 4 | 0 up, 0 down | Nov 5, 2024 | $15.85M |
| Jun 30, 2024 | -$0.15 | -$0.20 | N/A | +25.00% | Beat | N/A | 4 | 1 up, 1 down | Aug 6, 2024 | $15.81M |
| Mar 31, 2024 | -$0.14 | -$0.21 | N/A | +33.33% | Beat | N/A | 3 | 2 up, 0 down | May 7, 2024 | $15.78M |
| Dec 31, 2023 | -$0.37 | -$0.27 | -$0.29 - -$0.25 | -37.04% | Miss | N/A | 2 | 0 up, 0 down | Mar 5, 2024 | $17.05M |
| Sep 30, 2023 | -$0.14 | -$0.24 | N/A | +41.67% | Beat | N/A | 4 | 0 up, 1 down | Nov 7, 2023 | $16.30M |
| Jun 30, 2023 | -$0.25 | -$0.26 | -$0.38 - -$0.26 | +3.85% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2023 | $15.05M |
| Mar 31, 2023 | -$0.26 | -$0.28 | -$0.40 - -$0.27 | +7.14% | Beat | N/A | 5 | 0 up, 0 down | May 9, 2023 | $13.97M |
| Dec 31, 2022 | -$0.22 | -$0.36 | -$0.43 - -$0.32 | +38.89% | Beat | N/A | 5 | 0 up, 0 down | Mar 7, 2023 | $13.38M |
| Sep 30, 2022 | -$0.36 | -$0.36 | N/A | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 8, 2022 | $11.65M |
| Jun 30, 2022 | -$0.31 | -$0.39 | N/A | +20.51% | Beat | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | $11.67M |
| Mar 31, 2022 | -$0.34 | -$0.30 | -$0.36 - -$0.30 | -13.33% | Miss | N/A | 3 | 0 up, 0 down | May 10, 2022 | $11.67M |
| Dec 31, 2021 | -$0.28 | -$0.36 | -$0.37 - -$0.34 | +22.22% | Beat | N/A | 3 | 0 up, 0 down | Mar 15, 2022 | $10.94M |
| Sep 30, 2021 | -$0.30 | -$0.37 | -$0.39 - -$0.31 | +18.92% | Beat | N/A | 3 | N/A | Nov 10, 2021 | $10.36M |
| Jun 30, 2021 | -$0.31 | -$0.39 | -$0.40 - -$0.38 | +20.51% | Beat | N/A | 2 | N/A | Jul 23, 2021 | $10.18M |
| Mar 31, 2021 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 2, 2021 | $8.98M |
| Dec 31, 2020 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $7.83M |
| Dec 31, 2019 | -$0.27 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.80, after -$0.62 the year before. It was -$0.27 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.80 | N/A |
| Dec 31, 2024 | -$0.62 | N/A |
| Dec 31, 2023 | -$1.02 | N/A |
| Dec 31, 2022 | -$1.23 | N/A |
| Dec 31, 2021 | -$1.15 | N/A |
| Dec 31, 2020 | -$0.26 | N/A |
| Dec 31, 2019 | -$0.27 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,234 | 10 | |
| 2026Q2 | Jun 30, 2026 | 5,693 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,709 | 9 | |
| 2025Q4 | Dec 31, 2025 | 8,646 | 9 | |
| 2025Q3 | Sep 30, 2025 | 7,175 | 9 | |
| 2025Q2 | Jun 30, 2025 | 7,767 | 10 | |
| 2025Q1 | Mar 31, 2025 | 8,063 | 9 | |
| 2024Q4 | Dec 31, 2024 | 9,194 | 10 |
2026Q3 Earnings Call
Opening remarks
Kellen Sanger Head of Strategy Thank you, and good morning, everyone. Welcome to the SOPHiA GENETICS Third Quarter 2026 Earnings Conference Call. Joining me today to discuss our results are Ross Muken, our Chief Executive Officer; and George Cardoza, our Chief Financial Officer. I'd like to remind you that management will make statements during this call that are forward-looking statements within the meanings of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release issued by SOPHiA GENETICS today and in the documents and reports filed by SOPHiA GENETICS from time to time with the Securities and Exchange Commission. During this call, we will present both IFRS and non-IFRS financial measures. A reconciliation of IFRS to non-IFRS measures is included in today's earnings press release, which is available on our website. With that, I'll now turn the call over to Ross.
Ross Muken CEO Thanks, Kellen, and good morning, everyone. Q3 was another strong quarter for SOPHiA. We delivered 25% year-over-year revenue growth as demand for our platform continues to expand. Growth in the U.S. market remained robust. New products in Liquid Biopsy and Solid Tumor continue to gain adoption, and new BioPharma collaborations are establishing SOPHiA as a trailblazer in bringing clinical intelligence to patients around the globe. In addition to the strong growth, we also improved adjusted EBITDA materially in the third quarter by again dropping nearly 60% of our incremental revenue growth down to the bottom line, bringing us closer to profitability. Today, I'll update you on each of these areas and provide more details on the exciting path ahead. SOPHiA was founded with a vision to transform the world's health care data into actionable clinical intelligence for providers and patients. We started in genomics, where we've established ourselves as one of the largest diagnostic companies in the world. In Q3, the SOPHiA network performed 118,000 analyses on our platform, up 19% since last year. In other words, we analyzed roughly 40,000 patients per month across a network that spans 75 countries and 551 connected institutions globally. That network and the data flowing through it have allowed us to build one of the most sophisticated intelligence engines in health care. Every analysis run on our platform teaches our AI something new. It learns from a real-time, real-world data set that is unmatched in its breadth and diversity, including thousands of clinical contacts from patients in over 75 countries. And the learning doesn't stop with the data.
Frequently Asked Questions About SOPH
Did SOPH beat earnings estimates last quarter?
No. Sophia Genetics SA reported EPS of -$0.24 for the quarter ended Sep 30, 2026, below the -$0.13 estimate by 84.62%.
What EPS do analysts expect from SOPH next quarter?
The consensus EPS estimate for Sophia Genetics SA for the quarter ending Dec 31, 2026 is -$0.16 from 7 analysts, with estimates from -$0.20 to -$0.06.
How often does SOPH beat earnings estimates?
Sophia Genetics SA beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -17.05%.
SOPH pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts